September 2025 SCRI Release Copied

SCRI Trials and Trial Regimen Updates

The following updates were completed between Aug. 22 – Sept. 18. Sarah Cannon Research Institute now manages all SCRI/USOR trials and trial regimens.

For questions about these trials and regimens, please contact SCRIiKMEMRedits@McKesson.com.

New Builds Completed

Study Number Notes for New Build
25018 USOR 25018 GI 411 Phase 3 HLX22 or Placebo + Trastuzumab + Oxaliplatin + Capecitabine + Pembrolizumab or Placebo Q21D – v3.0 17DEC2024

USOR 25018 GI 411 Phase 3 HLX22 or Placebo + Trastuzumab + Oxaliplatin + Capecitabine Q21D – v3.0 17DEC2024

24321 USOR 24321 LYM 260 Phase 3 Golcadomide + Rituximab Q28D – 11FEB2025

USOR 24321 LYM 260 Phase 3 Rituximab + Bendamustine Q28D – 11FEB2025

USOR 24321 LYM 260 Phase 3 Rituximab + CHOP Q21D – 11FEB2025

USOR 24321 LYM 260 Phase 3 Rituximab + Lenalidomide Q28D – 11FEB2025

24059 USOR 24059 GYN 135 Phase 2 Part A R-DXd Q21D – v2.0 05FEB2025
24311 USOR 24311 BRE 460 Phase 1 Safety Cohort A1 Sacituzumab govitecan Q14D – 19NOV2024
24094 USOR 24094 BRE 457 Phase 3 Arm A PF-07220060 + Letrozole Q28D – 03SEP2024

USOR 24094 BRE 457 Phase 3 Arm B Letrozole + CDK4/6 Inhibitor Q28D – 03SEP2024

24185 USOR 24185 BRE 448 Phase 3 Arm A sac-TMT (MK-2870) Q84D 22NOV2024

USOR 24185 BRE 448 Phase 3 Arm B sac-TMT (MK-2870) + Pembrolizumab Q84D 22NOV2024

USOR 24185 BRE 448 Phase 3 Arm C Gemcitabine + Carboplatin Q84D 22NOV2024

USOR 24185 BRE 448 Phase 3 Arm C Nab-paclitaxel Q84D 22NOV2024

USOR 24185 BRE 448 Phase 3 Arm C Paclitaxel Q84D 22NOV2024

24266 USOR 24266 CLL 65 Phase 3 Arm A Sonrotoclax + Obinutuzumab Q28D – 13FEB2025

USOR 24266 CLL 65 Phase 3 Arm B Sonrotoclax + Rituximab Q28D – 13FEB2025

USOR 24266 CLL 65 Phase 3 Arm C Sonrotoclax + Obinutuzumab Q28D – 13FEB2025

USOR 24266 CLL 65 Phase 3 Arm D Venetoclax + Rituximab Q28D – 13FEB2025

24232 USOR 24232 LUN 581 Phase 3 Arm A NVL-655 Q28D – v2.0 06JUN2025

USOR 24232 LUN 581 Phase 3 Arm B Alectinib Q28D – v2.0 06JUN2025

Updated Reference Information

Study Number Updated Reference Information Updated Regimen Instructions Other Changes
24326 PM v3.0 29Apr2025 Regimen Comments; Admin and Observation Updated Drug Instructions
24312 PA 2.0; 25 July 2025 Regimen Comments: Admin Updated Drug Instructions and Premedication
24312 PM v1.1 04Mar2025 N/A Updated drug; Admin and Prep
24288 PM v1.0; 20 August 2025 N/A Updated drug instructions
24169 PA 2, 14APRIL2025 Regimen Comments: Admin Updated Drug Instructions
24150 PCL; 01 August 2025

PCL; 11 August 2025

N/A Updated drug frequency
24030 Version 3.0; 01 July 2025 Regimen comments; Admin Updated drug instructions and premedication
23340 PM v5.0; 13 August 2025 N/A Updated Dose/Form and instructions
23328 Version 2.0; 03MAR2025 N/A Updated drug instructions
23302 PM v2.0; 16th April 2025 N/A Updated drug instructions
23245 DIL; 27 August 2025 N/A New arms
23180 PA v3.0, 27May2025 Regimen Comments; Observation Updated drug instructions and premedication
23166 DIL; 14 August 2025 N/A Closed arms
23116 Amendment v6, 29APR2025 Regimen Comments: Admin Updated Admin/Prep and drug instructions
23084 PM v3.0; 21st August 2025 N/A Updated Drug instructions
22242 Version 6.0, 02MAY2025 N/A Updated drug; instructions, premedication, and frequency
22095 PA v9.0: 01 May 2025 Regimen comments: Admin Updated drug instructions
22026 PA8: 25 Feb 2025 Regimen comments: Admin, Prophylaxis, Premedication Updated drug; instructions and premedication
22026 Version 7.0; 07 August 2025 PACL; 11 August 2025 Regimen Comments; Admin and Observation Updated drug; Drug form, instructions, premedication, procurement
24326 Amendment 1 Version 2; 19MAR2025. Regimen comments; admin Updated drug; premedication

New Arms

24259 PM v2.0; 13th Feb 2025 N/A Updated drug; predication
23292 PA v18.0; 24 Feb 2025 Regimen Comments; Admin Updated drug; premedication

New arms

24130 PCL; 16 June 2025

PA v4.0; 26 June 2025

N/A Updated drug instructions and premedication